Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

Acute Heart Failure Market to Witness Upsurge in Growth, Examine DelveInsight | Key Companies in the Domain – AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Idorsia, Bristol-Myers Squibb, Novartis, Trevena, Scios

Published

on

<!– Name:DistributionId Value:8829874 –> <!– Name:EnableQuoteCarouselOnPnr Value:True –> <!– Name:IcbCode Value: –> <!– Name:CustomerId Value:1204938 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:347e9489-8b30-41e8-a620-f0e1380801b3 –>

New York, USA, May 02, 2023 (GLOBE NEWSWIRE) — Acute Heart Failure Market to Witness Upsurge in Growth, Examine DelveInsight | Key Companies in the Domain – AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company,  Idorsia, Bristol-Myers Squibb, Novartis, Trevena, Scios

The acute heart failure market dynamics are expected to change in 7MM in the coming years owing to the increasing research and development strategies, rising prevalence of the disease, increasing evidence-based therapies, growing aging of the population, and others. 

DelveInsight’s Acute Heart Failure Market Insights report includes a comprehensive understanding of current treatment practices, acute heart failure emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Takeaways from the Acute Heart Failure Market Report

  • As per DelveInsight analysis, the acute heart failure market is expected to grow positively owing to several underline factors during the study period (2019–2032).
  • DelveInsight’s analysis shows that acute heart failure cases show an increasing trend in the forecasted period in the 7MM. 
  • Leading acute heart failure companies such as Arena Pharmaceuticals, AstraZeneca, Palatin Technologies, Inc, Boehringer Ingelheim, Eli Lilly and Company, Aventyn, Inc., Corthera, Inc, Idorsia Pharmaceuticals Ltd., The Medicines Company, Bristol-Myers Squibb, Cardioxyl Pharmaceuticals, Inc, Nile Therapeutics, Trevena Inc., Scios, Inc., Novartis, and others are developing novel acute heart failure drugs that can be available in the acute heart failure market in the coming years.
  • Some of the key therapies for acute heart failure treatment include APD418, Dapagliflozin, PL-3994, Empagliflozin, COMPASSION Digital Biomarker, Relaxin, RLX030, Tezosentan, Clevidipine, CXL-1427, CD-NP, TRV027, BMS-986231, Nesiritide, LCZ696, and others.
  • Several acute heart failure therapies are awaiting approval, while some therapies are in the advanced stages of development. 

Discover which therapies are expected to grab the major acute heart failure market share @ Acute Heart Failure Market Report

Acute Heart Failure Overview

Heart failure is also known as congestive heart failure. It is also classified as left-side heart failure and right-side heart failure. The word corpulmonale refers to right-side heart failure caused by elevated blood pressure in the pulmonary arteries and right ventricle. There are two types of heart failure: acute and chronic. Acute heart failure has a fast onset and symptoms might occur without notice. However, with chronic heart failure, this challenge is continuing and long-term. It was shown that the majority of patients suffer from chronic heart failure. 

Acute heart failure is a syndrome characterized as the beginning or worsening of heart failure symptoms and signs, most of which are associated to systemic congestion. Acute heart failure is characterized clinically by symptoms and signs related to systemic congestion. Shortness of breath while moving or resting flat, also known as dyspnea, fatigue, swelling of the feet, ankles, legs, belly, or veins in the neck, are all acute heart failure symptoms. To diagnose acute heart failure patients, healthcare personnel conduct a fast assessment that includes the patient’s health history and a physical exam to learn about the symptoms of acute heart failure patients. 

Acute Heart Failure Epidemiology Segmentation

The acute heart failure epidemiology section provides insights into the historical and current acute heart failure patient pool and forecasted trends for the seven individual major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.

The acute heart failure market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Acute Heart Failure Prevalent Population
  • Acute Heart Failure Diagnosed Prevalent Population 
  • Acute Heart Failure Gender-specific Diagnosed Prevalent Cases 
  • Acute Heart Failure Age-specific Diagnosed Prevalent Cases 

Download the report to understand which factors are driving acute heart failure epidemiology trends @ Acute Heart Failure Epidemiological Insights

Acute Heart Failure Treatment Market 

Acute heart failure can be fatal; therefore, anyone experiencing symptoms should seek medical attention as soon as possible. Acute heart failure treatment focuses first on life-threatening symptoms, then on determining underlying causes and treating lingering symptoms. While heart performance improves, hospitalization is usually required. There are several possible treatments for acute heart failure. The treatment chosen will be determined by the person’s symptoms and the underlying issue that is producing them. As an example, Dyspnea: Supplemental oxygen is used to address this condition. The severity of dyspnea will determine whether oxygen is delivered through a nasal tube or a face mask. Sitting up straight can aid in breathing. Fluid buildup: Intravenous diuretics are used to treat fluid buildup within the body. Diuretics, as well as oxygen and heart failure medicines, will be used to treat pulmonary edema. 

The majority of people with acute heart failure have deteriorating chronic heart failure symptoms. Once the acute episode has been stabilized, various medications might be provided. The majority of these are vasodilators, which assist reduce blood pressure by widening blood vessels: Angiotensin-converting enzyme (ACE) inhibitors, which lower blood pressure and heart stress, Hydralazine, isosorbide, and angiotensin receptor blockers (ARB) are all blood pressure medications that operate by relaxing blood arteries. Aldosterone antagonists, which lower blood pressure by lowering sodium levels in the body; Beta blockers are medications that reduce blood pressure and slow the heart rate. Digoxin, which causes the heart to beat faster, Nitrates, which are typically used as a vasodilator when the patient also has pulmonary edoema, Pain relievers, such as morphine, may be beneficial in reducing anxiety in persons who are agitated and upset.

To know more about acute heart failure treatment, visit @ Acute Heart Failure Treatment Drugs 

Key Acute Heart Failure Therapies and Companies

  • APD418: Arena Pharmaceuticals
  • Dapagliflozin: AstraZeneca
  • PL-3994: Palatin Technologies, Inc
  • Empagliflozin: Boehringer Ingelheim/Eli Lilly and Company
  • COMPASSION Digital Biomarker: Aventyn, Inc.
  • Relaxin: Corthera, Inc
  • RLX030: Novartis
  • Tezosentan: Idorsia Pharmaceuticals Ltd.
  • Clevidipine: The Medicines Company
  • CXL-1427: Bristol-Myers Squibb/Cardioxyl Pharmaceuticals, Inc
  • CD-NP: Nile Therapeutics
  • TRV027: Trevena Inc.
  • BMS-986231: Bristol-Myers Squibb
  • Nesiritide: Scios, Inc.
  • LCZ696: Novartis

Learn more about the FDA-approved drugs for acute heart failure @ Drugs for Acute Heart Failure Treatment 

Acute Heart Failure Market Dynamics

The acute heart failure market is expected to change in the coming years. The rising healthcare spending across the globe is propelling the growth of the acute heart failure market. Moreover, the acute heart failure pipeline is highly robust; many possible therapies are being studied for acute heart failure treatment, and it is safe to assume that the therapeutic space will substantially impact the acute heart failure market throughout the forecast period. Furthermore, the expected introduction of emerging therapies with improved efficacy, more awareness initiatives programs, and a further improvement in the diagnosis rate are likely to boost the growth of the acute heart failure market in the 7MM.

However, certain factors may affect the growth of the acute heart failure market. The acute heart failure market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the acute heart failure market growth. Moreover, there are several generics, and off-label therapies that are available in the market for the treatment of patients affected by heart failure posing a threat to the acute heart failure market.

Report Metrics Details
Study Period 2019–2032
Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
Base Year 2019
Key Acute Heart Failure Companies Arena Pharmaceuticals, AstraZeneca, Palatin Technologies, Inc, Boehringer Ingelheim, Eli Lilly and Company, Aventyn, Inc., Corthera, Inc, Idorsia Pharmaceuticals Ltd., The Medicines Company, Bristol-Myers Squibb, Cardioxyl Pharmaceuticals, Inc, Nile Therapeutics, Trevena Inc., Scios, Inc., Novartis, and others
Key Acute Heart Failure Therapies APD418, Dapagliflozin, PL-3994, Empagliflozin, COMPASSION Digital Biomarker, Relaxin, RLX030, Tezosentan, Clevidipine, CXL-1427, CD-NP, TRV027, BMS-986231, Nesiritide, LCZ696, and others

Scope of the Acute Heart Failure Market Report

  • Therapeutic Assessment: Acute Heart Failure current marketed and emerging therapies
  • Acute Heart Failure Market Dynamics: Attribute Analysis of Emerging Acute Heart Failure Drugs
  • Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Unmet Needs, KOL’s views, Analyst’s views, Acute Heart Failure Market Access and Reimbursement

Discover more about acute heart failure drugs in development @ Acute Heart Failure Clinical Trials

Table of Contents

1. Acute Heart Failure Market Key Insights
2. Acute Heart Failure Market Report Introduction
3. Acute Heart Failure Market Overview at a Glance
4. Acute Heart Failure Market Executive Summary
5. Disease Background and Overview
6. Acute Heart Failure Treatment and Management
7. Acute Heart Failure Epidemiology and Patient Population
8. Patient Journey
9. Acute Heart Failure Marketed Drugs
10. Acute Heart Failure Emerging Drugs
11. Seven Major Acute Heart Failure Market Analysis
12. Acute Heart Failure Market Outlook
13. Potential of Current and Emerging Therapies
14. KOL Views
15. Unmet Needs
16. SWOT Analysis
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

Related Reports

Acute Heart Failure Pipeline

Acute Heart Failure Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key acute heart failure companies, including Windtree Therapeutics, Adrenomed, Arena Pharmaceuticals, Bristol-Myers Squibb, among others.

Acute Heart Failure Epidemiology Forecast

Acute Heart Failure Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted Acute Heart Failure epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Heart Failure Market

Heart Failure Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key heart failure companies, including Help Therapeutics, Heartseed, HAYA Therapeutics, GlaxoSmithKline, GB Sciences, Fujifilm Corporation, Evotec SE, Eli Lilly and Company, Edgewise Therapeutics, among others.

Advanced Heart Failure Pipeline

Advanced Heart Failure Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key advanced heart failure companies, including Sana Biotechnology, Salubris Biotherapeutics, Roche, Rivus Pharmaceuticals, Ribomic, Renova Therapeutics, Relaxera, among others.

Chronic Heart Failure Pipeline

Chronic Heart Failure Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key chronic heart failure companies, including Zensun (Shanghai) Sci & Tech, Cytokinetics, Mesoblast, Shanghai Hongyitang Biopharmaceutical Technology, Tasly Pharmaceuticals, among others.

Other Trending Reports

Treatment Resistant Depression Market | Advanced Renal Cell Carcinoma Market | Acute Heart Failure Market | Centronuclear Myopathy Market | Head And Neck Squamous Cell Carcinoma Market | Acquired Immunodeficiency Syndrome Market | Acute Intermittent Porphyria Market | Neurovascular Devices Market | Defibrillators Market | Ventricular Hypertrophy Market | Urolithiasis Market | Alopecia Areata Market | Autonomic Dysfunction Market | Acute Ischemic Stroke Ais Market | Adenoid Cystic Carcinoma Market | Aspergillosis Market | Biliary Atresia Market | Biliary Tumor Market | Chronic Inducible Urticaria Market | Chronic Insomnia Market | Critical Limb Ischemia Market | Endometriosis Pain Market | Generalized Anxiety Disorder Gad Market | Hallux Valgus Market | Hemophilia B Market | Immunologic Deficiency Syndrome Market | Neuromodulation Devices Market | Neurovascular Thrombectomy Devices Market | Osteosarcoma Market | Pemphigus Vulgaris Market | Progressive Familial Intrahepatic Cholestasis Market | Pruritus Market | Radiation Toxicity Market | Pulmonary Hypertension Associated With Interstitial Lung Disease Market | Cluster Headaches Market | Foot And Ankle Devices Market | Intravenous Immunoglobulin Market | Bile Duct Neoplasm Market | Blood Glucose Monitoring Systems Market | Rett Syndrome Market | Tissue Heart Valves Market | Cardiac Biomarkers Testing Devices Market | Subscription Healthcare | Hepatorenal Syndrome Market | Central Venous Catheters Market | Continuous Renal Replacement Therapy Machines Market | Nonalcoholic Steatohepatitis Market | Necrotizing Enterocolitis Market | Cardiac Amyloidosis Market | Artificial Iris Market | Aortic Aneurysm Stent Grafts Market | Polypoidal Choroidal Vasculopathy Market | Adrenal Crisis Market | Hearing Implants Market | Image Guided Surgery Devices Market | Angioedema Market | Bladder Cancer Market

Related Healthcare Blogs

Upcoming Cardiovascular Diseases Drugs

Key Companies in the Cardiology Segment

Heart Failure Market

Top Cardiac Devices in the Market

Related Healthcare Services

Healthcare Consulting

Healthcare Competitive Intelligence Services

Healthcare Asset Prioritization Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect with us on LinkedIn|Facebook|Twitter


GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

50 Scholarships Empowering STEM & Sustainability Education for UK Youth

Published

on

50-scholarships-empowering-stem-&-sustainability-education-for-uk-youth

NEW YORK, April 15, 2024 /PRNewswire/ — AFS Intercultural Programs, a global non-profit educational exchange organisation, is proud to announce the second year of Global STEM Innovators scholarships in the United Kingdom – equipping young people with access to STEM, sustainability, and global competence education.

The AFS Global STEM Innovators is a five-week, full-scholarship exchange program, for 50 youth (ages 14 to 17), that fosters the understanding and skills needed to help the world transition to a more sustainable future. The program combines an interactive virtual exchange focused on global skills, and a week-long, in-person workshop focused on innovations in STEM. Scholars will explore sustainability and social impact through diverse perspectives, innovations, and real-world case studies, including opportunities to meet with STEM industry leaders and experts.
Upon program completion, scholars earn the award-winning AFS Global Competence Certificate and are invited to join the AFS Global STEM alumni community, which offers mentorship, networking, and further academic and professional development opportunities.
Program Dates
Application Deadline: 15 May 2024Virtual Exchange: 8 July – 9 August 2024 (online)Workshop: 11-17 August 2024 (in-person)Eligibility
Legal residence in one of the following postcode areas: Aberdeen (AB), Cardiff (CF), Darlington (DL), Newport (NP), Swansea (SA), or Teesside (TS)Birthdate: 1 January 2007 – 31 July 2010AFS has partnered with Celtic English Academy in Wales to administer the program. Full scholarship funding is provided by bp, which supports AFS Global STEM programs to help build the STEM talent that the world needs to create sustainable solutions and improve the diversity of talent in STEM.
AFS brings decades of expertise in impact-driven educational exchange and the power of a global network. “We know that young people are eager to innovate and bring positive change to their communities, and we are proud to empower young people with critical global skills and knowledge, like cross-cultural communication, empathy, and conflict resolution,” says Daniel Obst, President & CEO of AFS. “Educating more young people to become global citizens is crucial to create a more sustainable future.”
To learn more or apply, please visit https://afs.org/global-stem/innovators/.
 
Photo – https://mma.prnewswire.com/media/2386290/AFS_Global_STEM_Innovators_UK.jpg
Logo – https://mma.prnewswire.com/media/1809272/AFS_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/50-scholarships-empowering-stem–sustainability-education-for-uk-youth-302117146.html

Continue Reading

Artificial Intelligence

Zimperium Positioned as the Leader in the 2024 SPARK MatrixTM for In-App Protection by Quadrant Knowledge Solutions

Published

on

zimperium-positioned-as-the-leader-in-the-2024-spark-matrixtm-for-in-app-protection-by-quadrant-knowledge-solutions

The Quadrant Knowledge Solutions SPARK Matrix™ provides competitive analysis & ranking of the leading In-App Protection vendors.Zimperium, with its comprehensive technology for In-App Protection, has received strong ratings across the parameters of technology excellence and customer impact.MIDDLETON, Mass., April 15, 2024 /PRNewswire/ — Quadrant Knowledge Solutions announced today that it has named Zimperium as the 2024 technology leader in the SPARK Matrix™: In-App Protection, Q2 2024.

 
The Quadrant Knowledge Solutions SPARK Matrix™ includes a detailed analysis of the global market dynamics, vendor landscape, and competitive positioning. The study also provides a competitive analysis and ranking of the leading In-App Protection providers in the form of the SPARK Matrix™. The study also provides strategic information for users to evaluate different vendor capabilities, competitive differentiation, and market positions.
Ayush Patidar, Analyst at Quadrant Knowledge Solutions, states, “Zimperium’s Mobile Application Protection Suite (MAPS) provides ‘shift left’ security to Android and iOS mobile applications through a unified security platform that protects sensitive user information through app shielding techniques and advanced cryptographic key protection capabilities. Zimperium has received strong ratings across technology excellence and customer impact and has been positioned as a leader in the SPARK Matrix: In-App Protection, Q1 2024.”
 “In-app protection capabilities enable seamless integration of security throughout the application lifecycle from development to runtime without slowing down releases.  The app’s comprehensive protection prevents reversing and tampering in app stores and defends against on-device threats,” said Krishna Vishnubhotla, Vice President of Product Marketing, Zimperium. “Being able to update the in-app detections and responses over the air is key as it allows security teams to keep up with evolving threats without having to release a new app every time.”
Additional Resources:
For more information about Zimperium, visit hereSPARK Matrix: In-App Protection, Q1 2024Complimentary Download – SPARK Matrix: In-App Protection, Q1 2024: LinkAbout Zimperium
Zimperium enables companies to realize the full potential of mobile-powered business by activating a Mobile-First Security Strategy. Built for the demands of mobile business, Zimperium’s Mobile-First Security Platform™ delivers unmatched security across both applications and devices. Only Zimperium delivers autonomous mobile security that dynamically adapts to changing environments so companies can securely capitalize on the new world of mobile-powered opportunities. Zimperium is headquartered in Dallas, Texas and backed by Liberty Strategic Capital and SoftBank. For more information, follow Zimperium on Twitter (@Zimperium) and LinkedIn, or visit www.Zimperium.com.
Zimperium Media Contacts:
Lisa Bergamo [email protected]  (650) 380-9250, Sena McGrand [email protected] (917) 941-4975
About Quadrant Knowledge Solutions
Quadrant Knowledge Solutions is a global advisory and consulting firm focused on helping clients in achieving business transformation goals with Strategic Business and Growth advisory services. At Quadrant Knowledge Solutions, our vision is to become an integral part of our client’s business as a strategic knowledge partner. Our research and consulting deliverables are designed to provide comprehensive information and strategic insights for helping clients formulate growth strategies to survive and thrive in ever-changing business environments.
For more available research, please visit https://quadrant-solutions.com/market-research/
Quadrant Media Contact:Mr. Ajinkya Ingle Quadrant Knowledge Solutions Regus Business Center 35 Village Road, Suite 100, Middleton Massachusetts 01949 United StatesEmail: [email protected] Phone: (+1) 978-344-2770
Content Source: https://quadrant-solutions.com/press-release/zimperium-positioned-as-the-leader-in-the-2024-spark-matrixtm-for-in-app-protection-by-quadrant-knowledge-solutions-544
Connect with us on LinkedIn- https://www.linkedin.com/company/quadrant-knowledge-solutions/
Logo: https://mma.prnewswire.com/media/746706/1470558/Quadrant_Knowledge_Solutions_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/zimperium-positioned-as-the-leader-in-the-2024-spark-matrixtm-for-in-app-protection-by-quadrant-knowledge-solutions-302117063.html

Continue Reading

Artificial Intelligence

Broadcom Earns Frost & Sullivan’s 2024 Global Company of the Year Award for Delivering Reliable and Flexible Hybrid Cloud Management Solutions

Published

on

broadcom-earns-frost-&-sullivan’s-2024-global-company-of-the-year-award-for-delivering-reliable-and-flexible-hybrid-cloud-management-solutions

Broadcom’s VMware software leads the industry with its innovative approach to hybrid cloud management, providing businesses with unparalleled visibility, automation, and control over diverse IT environments.
SAN ANTONIO, April 15, 2024 /PRNewswire/ — Frost & Sullivan recently researched the hybrid cloud management industry and based on its findings, recognizes Broadcom Inc. with the Global Company of the Year Award. This award is based on VMware software which Broadcom acquired in November 2023.

VMware software unifies and streamlines hybrid cloud environments and accelerates app innovation for the world’s most complex organizations. VMware hybrid cloud management solutions are globally recognized for their comprehensive features and integrations that extend visibility and control to Kubernetes environments and applications. VMware software, however, is unique based on in its integrated support for various infrastructures and its focus on automation to ensure consistent security and governance policies, reduce human error, and maintain budget alignment.
Through its acquisition of VMware, and with its strategic product development and highly innovative approach, Broadcom has solidified its position as a leader in the hybrid cloud management space. The company has solidified its position as a leader in the hybrid cloud management space by offering features not offered by other providers, including support for Kubernetes environments. Its hybrid management platforms support the widest variety of infrastructures and clouds in the market today, and recent enhancements have strengthened its security capabilities.
“Broadcom has earned its leadership position by acquiring VMware’s highly successful hybrid cloud platform. As Broadcom drives VMware’s roadmap for continued enhancements around app-aware infrastructure management comes to fruition, the company will experience continual growth as a market leader,” said Karyn Price, Industry Principal, ICT at Frost & Sullivan.
Recognizing the evolving needs of the global market, VMware successfully integrated new functionality by acquiring companies such as Mesh7 and SaltStack prior to the Broadcom acquisition. Mesh7 brought valuable API management capabilities, enhancing VMware’s service offerings, while SaltStack improved the company’s event-driven automation and security operations. This blend of strategic acquisitions with in-house platform development has allowed the company to offer a versatile solution that addresses a broad spectrum of cloud management demands.
Furthermore, VMware consistently demonstrated an unwavering commitment to organic growth, mainly through enhancing its app-aware infrastructure management capabilities. By consistently developing and updating its product suite, VMware ensured its offerings remained at the forefront of technology, catering to the dynamic needs of businesses undergoing digital transformation. In addition, Broadcom leverages generative artificial intelligence (AI) automation features, showing strategic thinking and leadership in platform growth and evolution. As a result, this commitment to innovation and growth positions VMware software as a key participant in the hybrid cloud management space, and Broadcom is expected to strengthen its market leadership in the next few years.
“With VMware software, Broadcom is one of the few providers that offers integrated support for APAC-based infrastructure providers and boasts the broadest variety of infrastructures supported on its hybrid cloud management platform,” noted Price.
Each year, Frost & Sullivan presents a Company of the Year award to the organization that demonstrates excellence, in terms of growth strategy and implementation in its field. The award recognizes a high degree of innovation with products and technologies and the resulting leadership, in terms of customer value and market penetration.
Frost & Sullivan Best Practices Awards recognize companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry.
About Frost & Sullivan
For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.
Contact:
Tarini SinghP: +91- 9953764546E: [email protected] 
Photo – https://mma.prnewswire.com/media/2386262/VMware_Award.jpg

View original content:https://www.prnewswire.co.uk/news-releases/broadcom-earns-frost–sullivans-2024-global-company-of-the-year-award-for-delivering-reliable-and-flexible-hybrid-cloud-management-solutions-302116082.html

Continue Reading

Trending